Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
PLoS One. 2018 Oct 31;13(10):e0204979. doi: 10.1371/journal.pone.0204979. eCollection 2018.
Type 3C Diabetes, or diseases of the exocrine pancreas has been reported to occur in approximately 30% of adult patient with pancreatitis. The incidence of glucose abnormalities or risk factors that may predict the development of abnormal glucose in the pediatric pancreatitis population is not known. We performed a retrospective chart review from 1998-2016 for patients who carry the diagnosis of acute pancreatitis (AP), acute recurrent pancreatitis (ARP), and chronic pancreatitis (CP). We extracted glucose values, HbA1c%, and data from oral glucose tolerance and mixed meal testing with timing in relation to pancreatic exacerbations. Patient characteristic data such as age, gender, body proportions, family history of pancreatitis, exocrine function and genetic mutations were also assessed. Abnormal glucose was based on definitions put forth by the American Diabetes Society for pre-diabetes and diabetes. Fifty-two patients had AP and met criteria. Of those, 15 (29%) had glucose testing on or after the first attack, 21 (40%) were tested on or after the second attack (in ARP patients) and 16 (31%) were tested after a diagnosis of CP. Of the patients tested for glucose abnormalities, 25% (13/52) had abnormal glucose testing (testing indicating pre-DM or DM as defined by ADA guidelines. A significantly higher proportion of the abnormal glucose testing was seen in patients (85%, 11/13) with a BMI at or greater than the 85th percentile compared to the normal glucose patients (28%, 11/39) (p = 0.0007). A significantly higher proportion of the abnormal glucose patients (77%, 10/13) had SAP during the prior AP episode to testing compared to the 10% (4/39) of the normal glucose patients (p<0.0001). Older age at DM testing was associated with a higher prevalence of abnormal glucose testing (p = 0.04). In our patient population, a higher proportion of glucose abnormalities were after the second episode of pancreatitis, however 62% (8/13) with abnormalities was their first time tested. We identified obesity and having severe acute pancreatitis (SAP) during the prior AP episode to testing could be associated with abnormal glucose. We propose that systematic screening for abnormal glucose after the first episode of acute pancreatitis in order to better establish the timing of diabetes progression.
3 型糖尿病,或外分泌胰腺疾病,据报道,在大约 30%的成年胰腺炎患者中发生。在儿科胰腺炎患者中,葡萄糖异常或可能预测葡萄糖异常发展的危险因素的发生率尚不清楚。我们对 1998 年至 2016 年期间患有急性胰腺炎 (AP)、复发性急性胰腺炎 (ARP) 和慢性胰腺炎 (CP) 诊断的患者进行了回顾性图表审查。我们提取了与胰腺恶化相关的时间的血糖值、HbA1c% 和口服葡萄糖耐量和混合餐测试数据。还评估了患者特征数据,如年龄、性别、身体比例、胰腺炎家族史、外分泌功能和基因突变。异常血糖是根据美国糖尿病协会提出的糖尿病前期和糖尿病的定义。52 名患者患有 AP 并符合标准。其中,15 名(29%)在首次发作时或之后进行了血糖检测,21 名(40%)在第二次发作时或之后进行了检测(在 ARP 患者中),16 名(31%)在 CP 诊断后进行了检测。在接受血糖异常检测的患者中,25%(13/52)的检测结果异常(ADA 指南定义的检测结果表明存在预糖尿病或糖尿病)。与血糖正常的患者(28%,11/39)相比,异常血糖检测结果明显更高的比例出现在 BMI 等于或大于第 85 百分位数的患者中(85%,11/13)(p=0.0007)。与血糖正常的患者(10%,4/39)相比,异常血糖患者中(77%,10/13)在先前 AP 发作期间有更高比例的 SAP(p<0.0001)。在 DM 检测时年龄较大与异常血糖检测的发生率较高相关(p=0.04)。在我们的患者人群中,第二次胰腺炎发作后葡萄糖异常的比例较高,但 62%(8/13)的异常患者是首次接受检测。我们发现肥胖和先前 AP 发作期间的严重急性胰腺炎(SAP)可能与葡萄糖异常有关。我们建议,为了更好地确定糖尿病进展的时间,应在首次急性胰腺炎发作后对异常血糖进行系统筛查。